CagriSema is an investigational drug candidate developed by Novo Nordisk for the treatment of obesity and type 2 diabetes. It combines two active ingredients: cagrilintide, a long-acting amylin analog, and semaglutide, a GLP-1 receptor agonist already marketed as Ozempic and Wegovy. The drug is administered as a once-weekly subcutaneous injection. In clinical trials, CagriSema has shown substantial weight loss, with phase 2 data from 2023 reporting average weight reductions of 15.6% over 32 weeks, compared to 5.1% for semaglutide alone and 8.1% for cagrilintide alone. The combination targets multiple appetite-regulating pathways, potentially offering better efficacy than existing single-agent therapies. The FDA approval process for CagriSema is closely watched because of the massive market for obesity drugs. The global anti-obesity drug market was valued at $24.6 billion in 2023 and is projected to exceed $100 billion by 2030. Novo Nordisk's semaglutide-based products already generated $31.4 billion in 2023 sales, but competition is intensifying. Eli Lilly's tirzepatide (Mounjaro/Zepbound) has demonstrated weight loss of up to 22.5% in phase 3 trials, setting a high efficacy bar. CagriSema aims to compete by combining mechanisms to achieve similar or better results with potentially fewer side effects. Novo Nordisk initiated two phase 3 trials for CagriSema in 2023: REDEFINE 1 (obesity) and REDEFINE 2 (type 2 diabetes with overweight or obesity). The REDEFINE program includes over 3,000 patients across multiple countries. Topline results from REDEFINE 1 are expected in late 2024 or early 2025. If successful, Novo Nordisk plans to submit a New Drug Application (NDA) to the FDA in 2025. The prediction market question specifically asks about FDA approval before a certain date, reflecting uncertainty about the timing and outcome of regulatory review. Interest in this prediction market stems from the high stakes involved. FDA approval of CagriSema would strengthen Novo Nordisk's position in the obesity market, potentially adding billions in annual revenue. It would also validate the combination therapy approach, encouraging other companies to develop similar dual-mechanism drugs. Failure or delay could open the door for competitors like Eli Lilly and Amgen. The approval decision also has implications for patients seeking more effective weight loss treatments, healthcare systems managing obesity-related costs, and investors tracking the pharmaceutical sector.

Historical Context

The development of CagriSema builds on decades of research into appetite regulation and metabolic disease. Amylin, a hormone co-secreted with insulin by pancreatic beta cells, was first identified in 1987. Early amylin analogs like pramlintide (Symlin) were approved in 2005 for diabetes but required multiple daily injections and caused nausea, limiting adoption. Cagrilintide, a long-acting amylin analog developed by Novo Nordisk, improves on pramlintide by requiring only weekly dosing and showing better tolerability in clinical trials. Semaglutide, the other component of CagriSema, has a more recent but dramatic history. Originally developed as a once-weekly GLP-1 receptor agonist for type 2 diabetes, semaglutide was approved as Ozempic in 2017. Its weight loss potential was confirmed in the STEP clinical program, leading to FDA approval of Wegovy (a higher-dose formulation) for obesity in June 2021. Wegovy's approval marked a turning point, as it was the first GLP-1 receptor agonist specifically approved for weight management since liraglutide (Saxenda) in 2014. The combination of amylin and GLP-1 receptor agonists was first tested in academic studies in the early 2010s. A 2014 study by Roth et al. found that co-administration of pramlintide and liraglutide in rodents produced greater weight loss than either agent alone. Novo Nordisk acquired rights to cagrilintide through its 2018 purchase of the Danish biotech Zealand Pharma's amylin analog program for $1.3 billion. Phase 1 trials of cagrilintide combined with semaglutide began in 2019, and positive phase 2 results were announced in 2022, showing the combination was well-tolerated and produced additive weight loss. Precedents for FDA approval of combination drugs in obesity exist. The FDA approved Contrave (naltrexone/bupropion) in 2014 and Qsymia (phentermine/topiramate) in 2012, both combination therapies for weight management. However, these drugs combine older agents with established safety profiles. CagriSema represents a newer approach, combining two relatively novel mechanisms. The FDA's willingness to approve such combinations will depend on robust safety data, particularly regarding gastrointestinal side effects, cardiovascular risk, and potential for thyroid C-cell tumors (a class concern for GLP-1 receptor agonists).